by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within non-Hispanic White (NHW) populations. Here we provide an extensive survey of the proteomic landscape of...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Development of Alzheimer’s disease (AD) pathology in Down’s syndrome (DS) occurs within a compressed timeline compared to sporadic or other genetic forms of AD. METHODS Plasma glial fibrillary acidic protein (GFAP) and plasma pTau-217...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract White matter hyperintensities (WMH) and infarcts found on magnetic resonance imaging (MR infarcts) are common biomarkers of cerebrovascular disease. In this review, we summarize the methods, publications, and conclusions stemming from the Alzheimer’s...
by Clinical Neuropsychologist | Tuesday, November 12, 2024 | Dementia
Abstract INTRODUCTION We investigate sex-specific topological structures associated with typical Alzheimer’s disease (AD) dementia using a novel state-of-the-art latent space estimation technique. METHODS This study applies a probabilistic approach for latent...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION Despite the recognized importance of including ethnic diversity in Alzheimer’s disease (AD) research, substantial knowledge gaps remain, particularly in Asian populations. METHODS RNA sequencing was performed on blood samples from the...
by Clinical Neuropsychologist | Friday, November 8, 2024 | Dementia
Abstract INTRODUCTION Semorinemab, an anti-tau monoclonal antibody, was assessed in two Phase II trials for Alzheimer’s disease (AD). Plasma and cerebrospinal fluid (CSF) biomarkers provided insights into the drug’s potential mechanism of action. METHODS...
